Literature DB >> 21706269

Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.

Yun-Ze Xu1, Yu Zhu, Zhou-Jun Shen, Jia-Yan Sheng, Hong-Chao He, Gui Ma, Yi-Cheng Qi, Ju-Ping Zhao, Yu-Xuan Wu, Wen-Bin Rui, Qing Wei, Wen-Long Zhou, Xin Xie, Guang Ning.   

Abstract

The purpose of this study was to determine the correlation between human adrenocortical carcinoma (ACC) and the proteins involved in tumor angiogenesis, and to evaluate the angiogenic status of ACC. The expression of heparanase-1 (HPA-1), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor-2 (VEGFR-2) as well as microvessel density (MVD) were measured in a series of tissue samples from 44 human sporadic adrenocortical tumors by immunohistochemistry. These specimens were classified as adenomas (n = 20) and carcinomas (n = 24) according to the histological criteria defined by Weiss. A total of 22 of 24 (91.67%) malignant cases showed positive staining for HPA-1 and 3 of 20 (15%) benign cases showed positive, the difference of HPA-1 expression between ACA and ACC was statistically significant (P < 0.001). Similarly, VEGF staining was seen in 70.83% (17/24) of the malignant cases versus 25% (5/20) of the benign, the difference of VEGF expression among two groups was statistically significant (P = 0.002). VEGFR-2 expressed highly in the ACC group (79.17%, 19/24) and lowly in the benign group (25%, 5/20), the two groups had extremely significant difference (P < 0.001). Malignant cases showed higher MVD compared to benign tumors (84.70 ± 12.44 vs. 21.05 ± 8.07, P < 0.001). HPA-1 and VEGF expression were positively correlated with MVD in all specimens (r_s = 0.812, P = 0.001; r_s = 0.834, P < 0.001). In conclusion, these results suggest that angiogenesis of human ACC maybe mediated by these proteins and they could represent selective targets for the molecularly targeted treatments of ACC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706269     DOI: 10.1007/s12020-011-9502-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  36 in total

Review 1.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

Review 2.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.

Authors:  I Vlodavsky; Y Friedmann
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

3.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.

Authors:  M D Hulett; C Freeman; B J Hamdorf; R T Baker; M J Harris; C R Parish
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

Review 4.  Management of patients with adrenal cancer: recommendations of an international consensus conference.

Authors:  D E Schteingart; G M Doherty; P G Gauger; T J Giordano; G D Hammer; M Korobkin; F P Worden
Journal:  Endocr Relat Cancer       Date:  2005-09       Impact factor: 5.678

5.  Contribution of the microvessel network to the clonal and kinetic profiles of adrenal cortical proliferative lesions.

Authors:  S J Diaz-Cano; M de Miguel; A Blanes; H Galera; H J Wolfe
Journal:  Hum Pathol       Date:  2001-11       Impact factor: 3.466

6.  What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?

Authors:  Martin Fassnacht; Bruno Allolio
Journal:  Clin Endocrinol (Oxf)       Date:  2010-11       Impact factor: 3.478

7.  Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.

Authors:  Kristoffer Staal Rohrberg; Birgit Guldhammer Skov; Ulrik Lassen; Ib Jarle Christensen; Gunilla Høyer-Hansen; Ian Buysschaert; Helle Pappot
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

8.  Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.

Authors:  Yu Zhu; Hong-chao He; Fei Yuan; Jun Zhang; Wen-bin Rui; Ju-ping Zhao; Zhou-jun Shen; Guang Ning
Journal:  Endocrine       Date:  2010-06-18       Impact factor: 3.633

9.  Angiogenic Index: A New Method for Assessing Microvascularity in Breast Carcinoma with Possible Prognostic Implications.

Authors:  Juan B. M. Laforga; F. Ignacio Aranda
Journal:  Breast J       Date:  2000-03       Impact factor: 2.431

Review 10.  Clinical review: Adrenocortical carcinoma: clinical update.

Authors:  Bruno Allolio; Martin Fassnacht
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

View more
  17 in total

Review 1.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

2.  Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis.

Authors:  Y Zhu; Y Xu; D Chen; C Zhang; W Rui; J Zhao; Q Zhu; Y Wu; Z Shen; W Wang; G Ning; X Wang
Journal:  Clin Transl Oncol       Date:  2013-11-01       Impact factor: 3.405

3.  The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

Authors:  Ciara O'Sullivan; Maureen Edgerly; Margarita Velarde; Julia Wilkerson; Aradhana M Venkatesan; Stefania Pittaluga; Sherry X Yang; Dat Nguyen; Sanjeeve Balasubramaniam; Tito Fojo
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

Review 4.  Novel targeted therapies in adrenocortical carcinoma.

Authors:  Bhavana Konda; Lawrence S Kirschner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-06       Impact factor: 3.243

5.  Heparanase-1 activities in the development of laser induced choroidal neovascularization.

Authors:  Wei-Qiang Tang; Bao-Ke Hou
Journal:  Int J Ophthalmol       Date:  2013-04-18       Impact factor: 1.779

6.  Heparanase-1 is downregulated in chemoradiotherapy orbital rhabdomyosarcoma and relates with tumor growth as well as angiogenesis.

Authors:  Wei-Qiang Tang; Yan Hei; Jing Lin
Journal:  Int J Ophthalmol       Date:  2022-01-18       Impact factor: 1.779

7.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

8.  Anoikis resistance: an essential prerequisite for tumor metastasis.

Authors:  Yong-Nyun Kim; Kyung Hee Koo; Jee Young Sung; Un-Jung Yun; Hyeryeong Kim
Journal:  Int J Cell Biol       Date:  2012-02-23

9.  Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes.

Authors:  João C D Muzzi; Jessica M Magno; Milena A Cardoso; Juliana de Moura; Mauro A A Castro; Bonald C Figueiredo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-14       Impact factor: 5.555

10.  Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo.

Authors:  Jun Zhang; Jian-min Yang; Hui-ju Wang; Guo-qing Ru; Dai-ming Fan
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.